TESTOSTERONE CYPIONATE INJECTION, USP 100 MG
TESTOSTERONE CYPIONATE : 100 MG · DIN 01977601 · STERIMAX INC
Health Canada status: CANCELLED POST MARKET
What is TESTOSTERONE CYPIONATE INJECTION, USP?
TESTOSTERONE CYPIONATE INJECTION, USP 100 MG contains TESTOSTERONE CYPIONATE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 01977601, held by STERIMAX INC, supplied as LIQUID for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 11-Mar-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TESTOSTERONE CYPIONATE INJECTION, USP used for?
Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01977601 |
|---|---|
| Brand name | TESTOSTERONE CYPIONATE INJECTION, USP |
| Generic / active ingredient | TESTOSTERONE CYPIONATE : 100 MG |
| Manufacturer | STERIMAX INC |
| Strength | 100 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAMUSCULAR |
| Schedule | CONTROLLED DRUGS (CDSA IV) |
| ATC code | G03BA03 TESTOSTERONE |
| AHFS class | 68:08.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 11-Mar-2025 |
| Original market date | 1992-12-31 00:00:00 |
How is it administered?
For intramuscular use only. Recommended dose: 200 mg administered intramuscularly every two weeks. Maximum dose: 400 mg per month. Adjust based on patient response.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15 and 30°C. Protect from light. Keep out of reach of children and pets.
How is it supplied?
100 mg per mL – In single dose ampoules of 2 mL each, with 5 ampoules per carton.
Contraindications
Not for use in women (especially pregnant/nursing). Known or suspected carcinoma of the prostate or breast in men. Hypersensitivity to any ingredients, including soy-synthesized testosterone.
Warnings and precautions
Not for athletic performance or body composition improvement. Risk of prostate hyperplasia/carcinoma in geriatrics. May increase blood pressure. Contains benzyl alcohol (risk in infants).
Is TESTOSTERONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for TESTOSTERONE CYPIONATE INJECTION, USP
What can be used instead?
Other Canadian products sharing ATC code G03BA03 TESTOSTERONE. 10 of 27 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANDROGEL | 1 % | GEL | BGP PHARMA ULC | MARKETED | DIN 02245345 |
| ANDROGEL | 1 % | GEL | BGP PHARMA ULC | MARKETED | DIN 02245346 |
| ANDROGEL | 12.5 MG | GEL | BGP PHARMA ULC | MARKETED | DIN 02249499 |
| NATESTO | 4.5 % | GEL | ACERUS BIOPHARMA INC | MARKETED | DIN 02450550 |
| TARO-TESTOSTERONE | 40 MG | CAPSULE | TARO PHARMACEUTICALS INC | MARKETED | DIN 02421186 |
| TARO-TESTOSTERONE CYPIONATE INJECTION | 100 MG | SOLUTION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02496003 |
| TARO-TESTOSTERONE GEL | 1 % | GEL | TARO PHARMACEUTICALS INC | MARKETED | DIN 02463792 |
| TARO-TESTOSTERONE GEL | 1 % | GEL | TARO PHARMACEUTICALS INC | MARKETED | DIN 02463806 |
| TESTIM 1% | 1 % | GEL | ENDO OPERATIONS LTD. | MARKETED | DIN 02280248 |
| TESTOSTERONE ENANTHATE INJECTION, USP | 200 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02536315 |
Who else supplies TESTOSTERONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TESTOSTERONE appears in 92 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.